Amphastar announces approval for glucagon for injection kit, 1mg

Rancho cucamonga, calif., dec. 29, 2020 (globe newswire) -- amphastar pharmaceuticals, inc., (nasdaq: amph) announced that the u.s. food and drug administration (“fda”) has approved its abbreviated new drug application (“anda”) for glucagon for injection emergency kit, 1 mg. glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. amphastar's newly approved synthetic peptide product was determined by the fda to be bioequivalent and therapeutically equivalent to eli lilly's glucagon emergency kit for low blood sugar, which has a recombinant dna (rdna)-origin.
AMPH Ratings Summary
AMPH Quant Ranking